WeVote
Log In

Bill

Bill

SF 4204

Psilocybin regulation provisions

2025-2026 Regular Session Introduced by Erin Maye Quade and 1 co-sponsor

Minnesota bill SF 4204 establishes regulatory framework for psilocybin access, likely enabling therapeutic or research use while creating state oversight mechanisms for production and distribution.

Referred to Judiciary and Public Safety
#boards #drugsandmedicine #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · SF 4204

Legislative bill overview

SF 4204 proposes regulatory frameworks for psilocybin in Minnesota, likely establishing controlled access pathways for therapeutic or research purposes. The bill would create state-level oversight mechanisms for psilocybin production, distribution, and use within defined parameters. This represents Minnesota's entry into the growing number of states reconsidering psilocybin policy following federal research reclassifications and clinical trial results.

Why is this important

Psilocybin research has shown promising results for treatment-resistant depression, PTSD, and end-of-life anxiety, creating pressure on state legislatures to enable access while maintaining public safety controls. Minnesota's regulatory approach could either expand patient access to emerging treatments or establish a cautious pilot program model that other states monitor. The bill's structure will significantly impact whether therapeutic benefits reach patients versus remaining limited to research settings.

Potential points of contention

  • Medical gatekeeping vs. access: Debate over whether regulations should prioritize broad patient eligibility or restrict access to narrowly-defined conditions and clinical settings only
  • Safety and enforcement concerns: Questions about dosing standards, provider training requirements, contamination prevention, and diversion to illegal markets versus overly restrictive rules that inhibit legitimate use
  • Federal-state legal conflict: Psilocybin remains a Schedule I controlled substance federally; the bill must navigate potential conflicts with DEA enforcement and whether it exposes participants to federal prosecution

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.